Core Insights - BillionToOne (BLLN) reported $96.05 million in revenue for the quarter ended December 2025, showing no year-over-year change, with an EPS of $0.11 compared to $0 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $85.85 million by +11.89%, and the EPS surpassed the consensus estimate of $0.07 by +69.23% [1] Financial Performance - Total tests delivered were 170,000, slightly below the average estimate of 172,644 based on two analysts [4] - The overall average selling price (ASP) was $561.00, exceeding the two-analyst average estimate of $484.19 [4] - Revenue from Prenatal services was $86.1 million, higher than the three-analyst average estimate of $75.37 million [4] - Revenue from Oncology services reached $9.1 million, compared to the $8.82 million average estimate based on three analysts [4] - Revenue from Clinical Trial Support and Other Services was $0.8 million, below the $1.28 million average estimate based on three analysts [4] Market Performance - Shares of BillionToOne have returned +0.5% over the past month, while the Zacks S&P 500 composite has decreased by -1.3% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]
BillionToOne (BLLN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates